AlphaYou
Overview
Smart money at a glance
Filings to Oct 2, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 1 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 2- Open
- $6.21
- 52-wk high
- $9.54
- High
- $6.36
- 52-wk low
- $4.73
- Low
- $6.12
- Prev close
- $6.15
- Mkt cap
- $651.3M
- Volume
- 677.5K
- Beta
- 0.40
- P/B
- 2.1x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -53.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about AURA filings
Are insiders buying or selling Aura Biosciences Inc (AURA) stock?
Neither. Aura Biosciences Inc (AURA) insiders filed no open-market purchases or sales in the 90 days to Oct 2, 2026, according to SEC Form 4 filings.
Which members of Congress have traded AURA recently?
None. No member of Congress disclosed a AURA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this AURA smart-money data?
This summary uses filings available on Oct 2, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (1)
- MC
Matrix Capital
$46.3M
sold
What insiders are doing
Sells (3)
- GA
Gibney Anthony S
$82K
sold
- MC
Matrix Capital
$39.0M
sold
- KC
Kilroy Conor
$82K
sold
How top traders are positioned
No tracked top-trader positions in AURA right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 17.1% below what analysts expected.
Earnings per share
-$0.41 expected
Reports Nov 12, 2026, in 41 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | $300.0K | -$600.0K | $274.0K | — |
| Gross profit | -$300.0K | $600.0K | -$274.0K | — |
| What it spent | ||||
| Research and development | $22.2M | $21.9M | $28.0M | $30.7M |
| Sales and admin | $5.7M | $5.3M | $6.9M | $17.3M |
| Total operating expenses | $27.9M | $27.2M | $34.9M | $48.1M |
| What was left | ||||
| Operating profit | -$27.9M | -$27.2M | -$34.9M | -$48.1M |
| Profit before tax | -$26.1M | -$25.5M | -$33.7M | -$45.6M |
| Tax | $26.0K | $15.0K | $11.0K | $29.0K |
| Net profit | -$26.1M | -$25.6M | -$33.7M | -$45.6M |
| EBITDA | -$25.8M | -$25.3M | -$32.5M | -$48.1M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace